727 - Case series on real-world experience of biologics in the management of atopic dermatitis in paediatric population at King’s College Hospital, London
Abstract
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory, pruritic skin disease. More than 50% of cases begin during the first year of life and at least 80% of affected children have onset before the age of 5. A bimodal distribution is seen, with the condition improving in late childhood and only a minority of cases persisting in adolescence and adulthood.
The widespread and persistent dermatitis and severe pruritus have a substantial impact on sleep and quality of life for both affected children and their parents. Childhood depression and anxiety can lead to negative parenting behaviours, affecting both children and parental well-being. In some cases, the dermatitis is complicated by secondary bacterial or viral infections.
New generation biologics and JAK inhibitors have emerged as a promising treatment option for moderate to severe cases of atopic dermatitis and transformed the face of dermatology.
This abstract presents a review of our experience in prescribing dupilumab and upadacitinib, in the management of AD among paediatric patients.
In this case series, we share our experience of using these new medications in managing paediatric atopic dermatitis. The majority of these patients had failed treatment with topical steroids, calcineurin inhibitors, and systemic immunosuppressants, or they have contraindications for prescribing immunosuppressors currently used as first step systemic treatment, e.g. patients with inflammatory bowel disease or liver transplant…
Read the paper
Related studies
- Tryptophan Metabolism and Gut-Brain Homeostasis
- Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review
- Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit
- Relationship between sleep disorders and gut dysbiosis: what affects what?
- The role of CLOCK gene in psychiatric disorders: Evidence from human and animal research
- Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.